Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Memento Medicines›
News
Memento Medicines

Memento Medicines

Series A

Memento Medicines is a Boston-based biotech developing biologic therapies for retinal diseases.

HQ
Boston, MA, US
Founded
2026
Loading
Overview
Analysis
Compare
Fundraising
Employees
News

Latest News About Memento Medicines

Memento Medicines launches with $93M Series A financing

The Pharma Letter

Memento Medicines launches with $93M Series A financing

Privately-held Boston-based biotech Memento Medicines completed a $93 million Series A financing to develop biologic therapies for retinal...

Jun 19, 2026

Memento Medicines Raises $93M in Series A Funding

FinSMEs

Memento Medicines Raises $93M in Series A Funding

Memento Medicines, a Boston, MA-based biotech developing biologic therapies for retinal diseases, raised $93M in Series A funding led by...

Jun 19, 2026

Memento Medicines Launches with $93 Million Series A Financing

Globe Newswire

Memento Medicines Launches with $93 Million Series A Financing

Memento Medicines announced the completion of a $93M Series A financing co-led by Forbion, RA Capital Management and Avego BioScience...

Jun 18, 2026

Brown Rudnick Advises Memento Medicines in $1 Billion Global License Agreement for Retinal Disease Therapy

Brown Rudnick

Brown Rudnick Advises Memento Medicines in $1 Billion Global License Agreement for Retinal Disease Therapy

Brown Rudnick represented Memento Medicines in its global license agreement with Korean biotechnology companies MabTics and Curacle for...

Jun 18, 2026

Memento Medicines launches with $93 million Series A to advance Tie2 activating bispecific for retinal disease

Ophthalmology Times

Memento Medicines launches with $93 million Series A to advance Tie2 activating bispecific for retinal disease

Memento Medicines launched with a $93 million Series A to advance MMT-205, a Tie2-activating and VEGF-inhibiting bispecific antibody for...

Jun 18, 2026

Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases

BioSpace

Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases

Memento Medicines launched with a $93 million Series A co-led by Forbion, RA Capital Management and Avego BioScience Capital, licensing...

Jun 18, 2026